Skip to search formSkip to main contentSkip to account menu

bexarotene 0.01 MG/MG Topical Gel [Targretin]

Known as: bexarotene 10 MILLIGRAM In 1 GRAM TOPICAL GEL [Targretin], Targretin 0.01 MG/MG Topical Gel, Targretin 1 % Topical Gel 
National Institutes of Health

Related topics

Related topics

9 relations
Butylated HydroxytolueneDehydrated AlcoholEthanolPolyethylene Glycol 400

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Monoclonal Antibody Therapy of T-Cell Leukemia and Lymphoma
T-cell leukemias and lymphomas are a heterogeneous group of uncommon tumors that account for 7-15% of lymphomas. [1] They… 
2013
2013
Total synthesis of targretin via palladium catalyzed crosscoupling reaction of a vinyl organozinc intermediate
In the last two decades, retinoids as isotretinoin, etretinate and acitretin have been utilized in treatment of primary cutaneous… 
2006
2006
Eine randomisierte Phase III Studie einer Kombinationstherapie Carboplatin/Paclitaxel mit oder ohne Bexarotene (Targretin®) bei nicht vortherapierten Patienten mit fortgeschrittenem oder…
2005
2005
O-086 A phase III randomized trial of carboplati/paclitaxel, with or without bexarotene (Targretin®), in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)
2003
2003
66 The combination of taxol and a selective retinoid X-receptor ligand targretin® (LGD1069) prevents and overcomes acquired taxol resistance in breast carcinoma
1997
1997
152 Targretin™, a selective retinoid X receptor ligand, vinorelbine and cisplatin for the treatment of non small cell lung cancer
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)